- Home
- ASM vs VOR Comparison
ASM vs VOR Comparison
Compare ASM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | VOR |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.0M | 1.1B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASM | VOR |
|---|---|---|
| Price | $5.62 | $19.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.18 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 3.1M | 1.7M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.35 | N/A |
| Revenue Next Year | $34.26 | N/A |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $1.62 |
| 52 Week High | $11.99 | $49.95 |
Technical Indicators
Market Signals| Indicator | ASM | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 56.67 |
| Support Level | $5.44 | $11.62 |
| Resistance Level | $5.87 | $19.70 |
| Average True Range (ATR) | 0.34 | 1.49 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 29.30 | 55.84 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.